The House Energy and Commerce Committee’s Subcommittee on Health recently held a hearing examining the drivers of rising health care costs. While much of the discussion focused on consolidation among providers, a key cause of that consolidation received far less attention: the Section 340B drug pricing program. As Charles Sauer Read more…
Healthcare is intensely personal, especially when devastating diagnoses arrive. Yet too often, a system weighed down by regulation and bureaucracy compounds that pain, forcing patients and families to navigate life-altering decisions without the support or flexibility they need. In a recent piece published on The Capitalist Substack, Market Institute President Read more…
In a recent column for RealClearMarkets, Market Institute Senior Fellow Norm Singleton examines how a well-intentioned federal program has morphed into a major source of wasteful healthcare spending and industry consolidation. Total healthcare spending is projected to reach nearly $6 trillion this year, with more than $2 trillion coming from Read more…
In a recent article for RealClearHealth, Market Institute President Charles Sauer warns that the Trump administration’s new TrumpRx initiative may deliver lower drug prices in the short run—but at the cost of future medical innovation. Sauer explains that while the goal of lowering pharmaceutical prices is laudable, the method matters. Read more…
As Congress revisits health reform, much of the debate still ignores the structural problems driving high premiums, limited choice, and a health care system that too often rewards bureaucracy over patients. In this virtual policy event, The Market Institute and the Goodman Institute convened three of the most influential voices Read more…
In a powerful Wall Street Journal essay, retired internal-medicine physician Brent Beasley recounts how he discovered—almost by accident—that he had Alzheimer’s disease at age 57. His story is not just personal. It is an indictment of a U.S. health care system that waits for crisis instead of preventing it. Beasley Read more…
As Congress debates whether to extend the Affordable Care Act’s enhanced insurance subsidies—originally enacted as part of the 2021 COVID relief bill—lawmakers face a familiar dilemma: preserve a failing system through temporary fixes or pursue reforms that empower patients and lower costs in the long run. In a recent article Read more…
This month, the Alzheimer’s Policy Working Group (APWG) released a new policy paper, Solving America’s Alzheimer’s Challenge, laying out a clinician-driven roadmap to improve how the U.S. diagnoses and manages Alzheimer’s disease—starting in primary care, where most patients first raise concerns. The paper reflects the real-world experience of frontline physicians Read more…
In a recent RealClearMarkets column, Charles Sauer examines the growing push to impose “most favored nation” (MFN) drug pricing through legislation expanding access to home infusion therapy—and explains why importing foreign-style price controls would ultimately hurt patients, not help them. Home infusion therapy allows millions of Americans with cancer, heart Read more…
Alzheimer’s disease is no longer just a medical challenge. It is a looming fiscal crisis—and one the United States is dangerously unprepared to confront. In a recent column published in The Capitalist, Charles Sauer argued that policymakers urgently need to recognize Alzheimer’s as an economic ticking time bomb. Without a Read more…